Please login to the form below

Not currently logged in
Email:
Password:

Stuart Collinson joins Silence Therapeutics

He replaces Simon Sturge as non-executive director

Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect.

The move follows Simon Sturge's resignation as non-executive director of the biotechnology company as he seeks to focus on his other business commitments.

Dr Collinson has held senior management roles in public and private life science companies across Europe and the US, including at GlaxoWellcome, now GlaxoSmithKline, Baxter International and Cabrellis Pharmaceuticals, now part of Celgene.

He is a partner of US-based VC firm Forward Ventures and currently also serves as chairman and chief executive officer of Tioga Pharmaceuticals and director for both Arcturus Therapeutics and Essentialis.

Chief executive officer of Silence Therapeutics Ali Mortazavi said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

21st January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics